1h Free Analyst Time
Alopecia - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H2 2020, provides an overview of the Alopecia (Dermatology) pipeline landscape.
Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 16, 8, 17 and 15 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAlopecia - Overview
Alopecia - Therapeutics Development
Alopecia - Therapeutics Assessment
Alopecia - Companies Involved in Therapeutics Development
Alopecia - Drug Profiles
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Alopecia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Companies, H2 2020 (Contd..2), H2 2020
- Products under Development by Companies, H2 2020 (Contd..3), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Alopecia - Pipeline by Aclaris Therapeutics Inc, H2 2020
- Alopecia - Pipeline by Addpharma Inc, H2 2020
- Alopecia - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Alopecia - Pipeline by Allergan Ltd, H2 2020
- Alopecia - Pipeline by Almirall SA, H2 2020
- Alopecia - Pipeline by AnTolRx Inc, H2 2020
- Alopecia - Pipeline by Applied Biology Inc, H2 2020
- Alopecia - Pipeline by Arena Pharmaceuticals Inc, H2 2020
- Alopecia - Pipeline by Berg LLC, H2 2020
- Alopecia - Pipeline by BiologicsMD Inc, H2 2020
- Alopecia - Pipeline by Bioniz Therapeutics Inc, H2 2020
- Alopecia - Pipeline by Bioquark Inc, H2 2020
- Alopecia - Pipeline by BirchBioMed Inc, H2 2020
- Alopecia - Pipeline by Brickell Biotech Inc, H2 2020
- Alopecia - Pipeline by BRIM Biotechnology Inc, H2 2020
- Alopecia - Pipeline by CarthroniX Inc, H2 2020
- Alopecia - Pipeline by Cassiopea SpA, H2 2020
- Alopecia - Pipeline by Chipscreen Biosciences Ltd, H2 2020
- Alopecia - Pipeline by Concert Pharmaceuticals Inc, H2 2020
- Alopecia - Pipeline by Eli Lilly and Co, H2 2020
- Alopecia - Pipeline by Energenesis Biomedical Co Ltd, H2 2020
- Alopecia - Pipeline by Exicure Inc, H2 2020
- Alopecia - Pipeline by Follica Inc, H2 2020
- Alopecia - Pipeline by Follicum AB, H2 2020
- Alopecia - Pipeline by Haplnscience Inc, H2 2020
- Alopecia - Pipeline by HCell Inc, H2 2020
- Alopecia - Pipeline by Histogen Inc, H2 2020
- Alopecia - Pipeline by Japan Tobacco Inc, H2 2020
- Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
- Alopecia - Pipeline by JW Pharmaceutical Corp, H2 2020
- Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2020
- Alopecia - Pipeline by Maxinovel Pharmaceuticals, H2 2020
- Alopecia - Pipeline by Mirae Cell Bio Co Ltd, H2 2020
- Alopecia - Pipeline by Moogene Medi Inc, H2 2020
- Alopecia - Pipeline by Nepsone ehf, H2 2020
- Alopecia - Pipeline by OliX Pharmaceuticals Inc, H2 2020
- Alopecia - Pipeline by Pfizer Inc, H2 2020
- Alopecia - Pipeline by Phio Pharmaceuticals Corp, H2 2020
- Alopecia - Pipeline by Quark Pharmaceuticals Inc, H2 2020
- Alopecia - Pipeline by RiverTown Therapeutics Inc, H2 2020
- Alopecia - Pipeline by Samson Clinical Pty Ltd, H2 2020
- Alopecia - Pipeline by Samumed LLC, H2 2020
- Alopecia - Pipeline by siRNAgen Therapeutics Corp, H2 2020
- Alopecia - Pipeline by Suzhou Kintor Pharmaceutical Inc, H2 2020
- Alopecia - Pipeline by Suzhou Ribo Life Sciences Co Ltd, H2 2020
- Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H2 2020
- Alopecia - Pipeline by TagCyx Biotechnologies, H2 2020
- Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2020
- Alopecia - Pipeline by Tigo GmbH, H2 2020
- Alopecia - Pipeline by Tritech Biopharmaceuticals Co Ltd, H2 2020
- Alopecia - Dormant Projects, H2 2020
- Alopecia - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Alopecia - Dormant Projects, H2 2020 (Contd..2), H2 2020
- Alopecia - Dormant Projects, H2 2020 (Contd..3), H2 2020
- Alopecia - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Alopecia, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aclaris Therapeutics Inc
- Addpharma Inc
- Alexion Pharmaceuticals Inc
- Allergan Ltd
- Almirall SA
- AnTolRx Inc
- Applied Biology Inc
- Arena Pharmaceuticals Inc
- Berg LLC
- BiologicsMD Inc
- Bioniz Therapeutics Inc
- Bioquark Inc
- BirchBioMed Inc
- Brickell Biotech Inc
- BRIM Biotechnology Inc
- CarthroniX Inc
- Cassiopea SpA
- Chipscreen Biosciences Ltd
- Concert Pharmaceuticals Inc
- Eli Lilly and Co
- Energenesis Biomedical Co Ltd
- Exicure Inc
- Follica Inc
- Follicum AB
- Haplnscience Inc
- HCell Inc
- Histogen Inc
- Japan Tobacco Inc
- Jiangsu Hengrui Medicine Co Ltd
- JW Pharmaceutical Corp
- Kuhnil Pharmaceutical Co Ltd
- Maxinovel Pharmaceuticals
- Mirae Cell Bio Co Ltd
- Moogene Medi Inc
- Nepsone ehf
- OliX Pharmaceuticals Inc
- Pfizer Inc
- Phio Pharmaceuticals Corp
- Quark Pharmaceuticals Inc
- RiverTown Therapeutics Inc
- Samson Clinical Pty Ltd
- Samumed LLC
- siRNAgen Therapeutics Corp
- Suzhou Kintor Pharmaceutical Inc
- Suzhou Ribo Life Sciences Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- TagCyx Biotechnologies
- Taisho Pharmaceutical Holdings Co Ltd
- Tigo GmbH
- Tritech Biopharmaceuticals Co Ltd
